Methods of treating intraocular pressure with activators of Tie-2
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma.
1. A method for reducing intraocular pressure in a subject having elevated intraocular pressure, the method comprising administering to the subject a therapeutically-effective amount of a Tie-2 activator, wherein:
the administration reduces the intraocular pressure by about 0.1 mmHg to about 9 mmHg compared to absence of administration;
the subject expresses Ang-1 and Ang-2;
the subject is human; and
the Tie-2 activator is a compound of the formula:
or a pharmaceutically-acceptable salt or zwitterion thereof.
2. The method of claim 1 , wherein the administration is to an eye of the subject.
3. The method of claim 1 , wherein the administration is intravitreal.
4. The method of claim 1 , wherein the administration reduces the intraocular pressure by at least about 2 mmHg within 28 days of administration compared to absence of administration.
5. The method of claim 1 , wherein the subject has glaucoma, wherein the intraocular pressure is associated with the glaucoma.
6. The method of claim 1 , wherein the compound reduces intraocular pressure by stabilizing vasculature associated with a trabecular meshwork in the subject.
7. The method of claim 1 , wherein the therapeutically-effective amount is from about 1 mg to about 300 mg.
8. The method of claim 1 , wherein the therapeutically-effective amount is from about 0.5 mg to about 30 mg.
9. The method of claim 1 , wherein the intraocular pressure is ocular hypertension.
10. The method of claim 9 , wherein the subject has glaucoma, wherein the ocular hypertension is associated with glaucoma.